The three things that trigger an FDA warning letter

FDA warning letters to peptide sellers are public documents. You can read them. And when you read enough of them next to each other, the same three patterns show up again and again.

That is genuinely useful, because it means enforcement in this category is not arbitrary. It is pattern-matching against specific, avoidable things, and every one of them is a decision somebody made about their own marketing.

1. Human-use language anywhere in your marketing

This is the big one, and the word doing the work is anywhere.

Operators tend to assume the research-use-only disclaimer on the product page is the thing being evaluated. It is not. FDA looks at the totality of how a product is marketed, which includes your blog, your email, your social posts, your product descriptions, and copy you did not write yourself.

The categories that recur: recovery language, muscle-building framing, weight-loss framing, and anti-aging claims. A disclaimer at the bottom of a page does not neutralise a headline at the top of it.

The practical test I use: if every disclaimer were deleted from the site, what would a reasonable person conclude this product is for? If the answer is “taking it,” the disclaimer is not doing what you think it is doing.

2. Shipping human-use accessories

This is the one that surprises people, and it is the most important thing in this article.

FDA has explicitly cited co-selling bacteriostatic water for injection as evidence of intent, on the reasoning that offering it alongside the compound “demonstrates that you intend for [the product] to be used in combination for injection.”

Read that carefully. The finding was not based on anything the seller wrote. It was based on what was in the cart. You can have flawless copy, a clean disclaimer, and no claims anywhere on the site, and still hand a regulator a documented statement of intent through your product catalogue.

The same logic extends to anything that only makes sense if a human is going to use the product: syringes, needles, alcohol swabs, dosing calculators, and bundles that pair a compound with the equipment for administering it.

If you sell research compounds, sell research compounds.

3. Referencing FDA-approved drug names

Using trademarked pharmaceutical brand names in product descriptions or marketing is the third recurring trigger. Naming an approved drug alongside your product invites the comparison you least want a regulator to draw: that yours is an alternative to an approved medicine, which is a claim you are not in a position to make.

This shows up in subtler forms than the obvious one. “A more affordable alternative to [brand].” “The same active as [brand].” Comparison tables. Search-optimised pages built around a branded drug name to capture its traffic. That last one is common and is a poor trade: the traffic is real, and so is the evidentiary record you have created.

What the enforcement record looks like

These are public. Reading a couple of them in full is worth more than any summary, including this one:

• Summit Research Peptides, December 2024
• USApeptide.com, February 2025

In April 2026 FDA took coordinated action across seven sites at once, which is the part of the trend worth noting. Enforcement in this category has moved from occasional individual letters toward batched, sweep-style actions, and more than 50 warning letters went to peptide sellers in 2025 alone.

It is also worth being straight about the ceiling: escalation beyond warning letters to inspections and criminal referral has occurred in this space. Exactly what distinguishes a criminal referral from a civil-only matter is not something any public document sets out clearly, so treat anyone who tells you they know the threshold with suspicion, and talk to qualified defence counsel rather than a blog if you have received anything from FDA.

Before and after

Most of this is fixable at the copy level. Some examples of the shape of the change:

• “Supports faster recovery from training” → describe what the compound is and what it is studied for, without asserting an outcome in a person
• “Our BPC-157 helps heal tendons” → “BPC-157, research use only. Certificate of analysis on every lot.”
• “A cost-effective alternative to [approved drug]” → remove entirely. There is no compliant version of this sentence.
• “Stack for cutting” → drop the protocol framing; bundles organised around human outcomes are the human-use claim

The pattern is the same each time: describe the compound and your quality process, not what happens to a person who uses it. That leaves you plenty to say. Purity, third-party testing, lot traceability, storage handling, shipping, and documentation are all real differentiators, and they are the things a serious buyer is evaluating anyway.

Why this is also a payments problem

One more reason to take it seriously, beyond the regulator: your processor is reading the same site.

Payment risk teams use automated keyword and pattern detection, and copy that approaches drug-like framing scores the same whether or not FDA ever looks at it. A documented enforcement history across the category is exactly what an acquiring bank cites when it declines a merchant. Marketing copy is not separate from your payment stability. It is an input to it.

This guide is general information, not legal advice. It summarises publicly available FDA enforcement records and describes patterns visible in them; it is not a prediction of how any agency will treat your business. Enforcement priorities and regulatory status change. Consult qualified regulatory counsel about your own products and marketing, and about any communication you receive from a regulator.